glaucoma Combination of Sequencing, EHR Data Links Genes to Range of Conditions The exome-by-phenome-wide analysis uncovered 21 novel gene-phenotype associations, including genes linked to glaucoma and diabetes. Glaucoma Protective Variants Uncovered in Genetic Data From UK, Finland With UK Biobank and FinnGenn data, researchers tracked down rare changes in the angiopoietin-like 7 gene that coincide with lower glaucoma and intraocular pressure risk. Glaucoma Polygenic Risk Score Emerges From Multi-Trait Analysis in UK Biobank Participants The new PRS could help identify people at increased risk who may benefit from earlier screening and treatment to prevent blindness. Glaucoma Diagnostic Targeted by Mannin Research, McMaster University Collaboration The test will be designed to detect a protein biomarker in aqueous humor that can be used to determine the severity of glaucoma and to make treatment decisions. Glaucoma Risk Factor Linked to More Than 100 Genetic Loci in Europeans Through a meta-analysis of nearly 140,000 people, an international team of researchers tied 112 loci to increased intraocular pressure, a glaucoma risk factor. Feb 8, 2018 Q Biomed Options Glaucoma Biomarker From WUSTL Oct 2, 2017 CRISPR Editing in Mice Disrupts Glaucoma-Causing Gene Mutation Jan 11, 2016 Through GWAS Meta-Analysis, Researchers Link Three Genes to Glaucoma Sep 10, 2015 Two Risk Genes Interact to Cause Primary Open-Angle Glaucoma Jun 26, 2014 Quark Begins Enrollment in Glaucoma Drug Trial Premium Oct 31, 2013 Sylentis Sees Phase III Trial for Glaucoma Drug by 2015 Premium Oct 15, 2013 UCSD-led Glaucoma Genes Study Lands $6.4M Apr 18, 2013 NIH Awards Nearly $2M in microRNA Research Grants Premium Jul 5, 2012 Sylentis Preps to Move Glaucoma Drug into Phase II Next Year Premium May 3, 2012 Quark to Run Phase IIa Trial of RNAi Drug in Glaucoma Premium Feb 9, 2012 Quark Still Sees IPO as a Possibility as Phase II Trials Near Completion Premium Jan 12, 2012 Quark Releases Positive Phase I Data on Ocular Neuroprotectant Premium Nov 17, 2011 Sylentis Picks up Option to Alnylam RNAi IP Premium Sep 13, 2010 Decode-Led GWAS Uncovers Glaucoma Risk Variant Jul 8, 2010 Sylentis Concludes Phase Ia Study of Glaucoma Drug Premium Apr 1, 2010 Sylentis Eyes Second Part of Phase I/II Trial for Glaucoma Rx, Searches for Partners Premium Mar 4, 2010 Quark Begins Patient Dosing in Phase I Study of Ocular Neuroprotectant Premium Dec 3, 2009 Quark Aims for Five Clinical Indications, New IND in 2010 Premium Aug 20, 2009 Sylentis Aims to Begin Phase I Study of Glaucoma Drug in September Premium Jul 30, 2009 Quark to File IND for Eye Disease Rx in September; New Data Shows It May Treat Glaucoma Premium Load More Breaking News Eagle Biosciences, Genetic Analysis Ink Distribution Agreement for Gut Microbiota Test Centogene Q1 Revenues Grow More Than Fivefold Driven by COVID-19 Testing Epizyme Partnering With Quest Diagnostics for Lymphoma Mutation Testing Enzo Biochem, CLX Health Partner to Support COVID-19 Testing for International Travel Type 1 Diabetes GWAS, Fine-Mapping Leads to New Genetic Loci, Potential Drug Targets LSU Health Sciences Center Wins $2.4M to Lead SARS-CoV-2 Variant Sequencing Program The Scan Missed Early Cases A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports. Limited Journal Editor Diversity A survey finds low diversity among scientific and medical journal editors, according to The Scientist. How Much of a Threat? Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned. PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.